The Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has voted to expand routine and catch-up HPV vaccination in males through 26 years of age who are inadequately vaccinated. In addition, the ACIP recommended HPV vaccination for adults aged 27 to 45 who are not adequately vaccinated based on shared clinical decision making.
Details of the ACIP recommendations will be reviewed by the director of the CDC and the Department of Health and Human Services and published in the CDC’s Morbidity and Mortality Weekly Report (MMWR).
Currently, the CDC recommends routine HPV vaccination at age 11 or 12 years; vaccination can be given starting at 9 years of age. The recommendations also include vaccination for females through age 26 years and for males through age 21 years who were not adequately vaccinated previously. Approval of the new ACIP recommendations would harmonize the age recommendations for males and females.
Commenting on the ACIP vote, Christopher M. Zahn, MD, VP of Practice Activities at the American College of Obstetricians and Gynecologists (ACOG) said, “Today’s decision from ACIP emphasizes […] that the HPV vaccine is safe and effective for use in patients ages 27 to 45, and that use of the vaccine in this age group should be the result of shared decision making between patients and their trusted physicians.”
Findings from a recent systematic review and meta-analysis published in The Lancet, demonstrated “compelling evidence” of the impact of routine HPV vaccination on reducing HPV infections as well as HPV-related diseases. The study included data from 60 million patients.
For more information visit cdc.gov.
This article originally appeared on MPR